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Abstract
This study aimed to investigate the diagnostic accuracy of the Fetal Medicine Foundation (FMF) Bayes theorem-based
model for the prediction of preeclampsia (PE) at 11–13 weeks of gestation in the Japanese population. In this prospective
cohort study, we invited 2655 Japanese women with singleton pregnancies at 11–13 weeks of gestation to participate, of
whom 1036 women provided written consent. Finally, we included 913 women for whom all measurements and perinatal
outcomes were available. Data on maternal characteristics and medical history were recorded. Mean arterial pressure (MAP),
uterine artery pulsatility index, and maternal serum placental growth factor (PlGF) were measured. The patients delivered
their babies at Showa University Hospital between June 2017 and December 2019. Participants were classified into high-
and low-risk groups according to the FMF Bayes theorem-based model. Frequencies of PE were compared between groups.
The screening performance of the model was validated using the area under receiver operating characteristic (AUROC)
curve. A total of 26 patients (2.8%) developed PE, including 11 patients (1.2%) with preterm PE (delivery at <37 weeks).
The frequency of preterm PE was significantly higher in the high-risk group than in the low-risk group (3.8% vs. 0.2%, p <
0.05). This population model achieved a 91% detection rate for the prediction of preterm PE at a screen-positive rate of 10%
by a combination of maternal characteristics, MAP, and PlGF. The AUROC curve for the prediction of preterm PE was
0.962 (0.927–0.981). In conclusion, the prediction of preterm PE using the FMF Bayes theorem-based model is feasible in
the Japanese population.
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Introduction
In recent years, it has been suggested that the prophylactic
use of low-dose aspirin beginning before 16 weeks of
gestation could reduce the prevalence of preeclampsia (PE)
by 50% compared with its use after 16 weeks of gestation
[1]. It is therefore important to provide early screening and
identify pregnant women at high risk of developing PE who
might benefit from aspirin prophylaxis [2]. Early screening
and management are also associated with improved neo-
natal outcomes [3]. Several risk factors have been reported
as predictors of PE [4–6]. The traditional approach to
screening PE is to identify risk factors from maternal
characteristics and medical history, but such an approach
can identify only 40% of preterm PE cases with delivery at
<37 weeks of gestation at a screen-positive rate of 10% [7].
Recently, the Fetal Medicine Foundation (FMF) proposed a
Bayes theorem-based model to predict preterm PE using a
combination of maternal characteristics, medical history,
mean arterial pressure (MAP), uterine artery pulsatility
index (UtA-PI), and serum placental growth factor (PlGF).
According to the risk calculation with the use of this
combined prediction algorithm, women are classified into
high- and low-risk groups. This model combines the a priori
risk from maternal characteristics and medical history
(maternal factors) with the results of various combinations
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of biophysical and biochemical measurements and can
predict ~90% of early PE cases, with delivery at <32 weeks
of gestation and 75% of preterm PE cases, with delivery at
<37 weeks of gestation, at a screen-positive rate of 10%
[4, 6]. Although this model has taken different ethnic
backgrounds into account, it is uncertain whether Japanese
and European pregnant women have different reference
values for biophysical and biochemical markers. It is
important to clarify whether the FMF Bayes theorem-based
model is applicable for clinical use in Japan. Therefore, the
objective of this study was to assess the screening perfor-
mance of the FMF Bayes theorem-based model in the
Japanese population at 11–13 weeks of gestation.
Methods
Study design and patients
This prospective observational cohort study was conducted
at Showa University Hospital in Tokyo, Japan. Eligibility
criteria for this study were maternal age, ≥18 years; no
serious mental illness or learning disabilities; and singleton
pregnancy with a live fetus with no major abnormality
identified at 11–13 weeks of gestation. Based on these
criteria, we invited 2655 Japanese women to participate in
the study, and 1035 women provided consent. Subse-
quently, we excluded 122 cases (12%) due to missing
ultrasound measurement data (n= 17), biomarker data (n=
39), or outcome data (n= 44). Additionally, cases in which
pregnancy resulted in miscarriage before 22 weeks of
gestation (n= 2) or termination of pregnancy (n= 20) were
excluded. As a result, 913 women were included in the
present study (Fig. 1). All enrolled subjects were followed
up and delivered at our hospital between June 2017 and
December 2019.
The study was approved by the Ethics Committee of our
hospital (#2270). The confidentiality of the patients
involved was protected, and no personal data were required
for this study. All eligible women were provided with
written information about the study, and those who
agreed to participate provided written informed consent.
This paper is an expanded Japanese series that included a
number of women who participated in a previous
study that evaluated the screening performance of first-
trimester prediction models for preterm PE in a large Asian
population [6].
Study variables
All pregnant women at 11–13 weeks of gestation underwent
ultrasonography for the measurement of fetal crown rump
length (CRL) and assessment of fetal morphological
abnormalities. At the same time, the measurement of UtA-
PI was performed. Maternal characteristics and medical
history, which consisted of gestational age, maternal age,
weight, height, ethnic origin (East Asian), method of con-
ception, smoking, chronic hypertension (CH), preexisting
diabetes mellitus, systemic lupus erythematosus/antipho-
spholipid syndrome, parity, history of PE, and family
Fig. 1 Flow chart depicting the
study population, inclusion, and
exclusion criteria
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history of PE, were recorded. Gestational age was deter-
mined by the fetal CRL at 11–13 weeks.
The MAP was measured by validated automated devices
(Omron HCR-7101 sphygmomanometer, Omron Health-
care Co., Ltd., Japan) according to the standardized protocol
by the nurses who had received appropriate training on the
use of the device [8]. The women were placed in a sitting
position with their arms supported at the heart level. Small
(<22 cm), normal (22–32 cm), and large (33–42 cm) adult
cuffs were used depending on the mid-upper arm cir-
cumference. After a 5-min rest, blood pressure was mea-
sured in both arms simultaneously, and each measurement
was repeated at a 1-min interval. When the last two blood
pressure measurements in either arm differed by more than
10 mmHg for systolic and 6 mmHg for diastolic blood
pressure, additional recordings were made from both arms
until variations between consecutive readings fell within 10
mmHg of the systolic and 6 mmHg of the diastolic blood
pressure. We calculated the MAP from the average of all
four measurements.
The left and right UtA-PI were measured using trans-
abdominal color Doppler ultrasonography, and the average
values were recorded. The transabdominal approach for the
assessment of UtA-PI followed the standardized protocol
[9]. Midsagittal sections of the uterus and cervix were
initially visualized. The transducer was gently tilted side-
ways so that the uterine arteries with high blood flow
velocity along the side of the cervix and uterus (at the level
of the internal os) could be identified using color flow
mapping. Pulsed wave Doppler sample volume was set
narrow (at ~2 mm) and positioned on either the ascending or
descending branch of the uterine artery, at the point closest
to the internal cervical os, with an insonation angle of <30°.
The peak systolic velocity of >60 cm/s was used to verify
that the uterine artery was being examined [10].
Maternal serum concentrations of PlGF were measured
by an automated analyzer: DELFIAⓇ Xpress system (PlGF
1-2-3 kits; DELFIA Xpress random access platform; Per-
kinElmer Inc, Waltham, MA). All ultrasound operators
obtained the appropriate certificate from the FMF.
The measured values of MAP, UtA-PI, and PlGF were
converted into multiple of the median (MoM) values using
the application, and then the risks were calculated using the
prediction model in individual cases. The cutoff values for
high-risk status were set to 1/100 for preterm PE and 1/50
for term PE.
Definitions
PE was defined as gestational hypertension accompanied by
proteinuria or other maternal organ dysfunctions at or after
20 weeks of gestation with all symptoms normalizing by
12 weeks postpartum, according to the Japan Society for the
Study of Hypertension in Pregnancy [11, 12]. Proteinuria is
not mandatory for the diagnosis of PE. Rather, PE is
diagnosed by the presence of de novo hypertension after
20 weeks of gestation accompanied by proteinuria and/or
evidence of maternal acute kidney injury, liver dysfunction,
neurological features, hemolysis or thrombocytopenia, or
fetal growth restriction.
Systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg on at least 2 occasions, 4 h apart,
was defined as CH.
Proteinuria was defined as protein excretion of ≥300 mg/
day in a 24-h urine collection.
Superimposed PE was defined as CH diagnosed before
20 weeks of gestation, with proteinuria emerging afterward.
Superimposed PE was included as PE in this study.
Researchers reconfirmed the clinical diagnosis determined
by the clinicians to enhance accuracy. Preterm and term PE
were defined as PE with delivery at <37 and ≥37 weeks of
gestation, respectively. Data on perinatal outcomes were
collected from the hospital maternity records.
Statistical analysis
The data were analyzed using a computerized data analysis
program (Statistical Package for Social Science (SPSS) for
Windows, version 20.0 J; Chicago, IL, USA). Continuous
variables are presented as the median (range). The
Mann–Whitney U-test was used to compare continuous
variables including MAP, UtA-PI, and serum concentra-
tions of PlGF between the high- and low-risk groups.
Categorical variables are presented as counts and percen-
tages and were compared using Fisher’s exact test or the
chi-squared test. Statistical significance was defined as a p
value of less than 0.05. Multiple comparisons between
preterm PE, term PE, and unaffected groups were per-
formed with the Mann–Whitney test and chi-squared test
with Bonferroni correction. Discrimination was assessed by
area under the receiver operating characteristic (AUROC)
curve, and detection rates for fixed false-positive rates were
5, 10, and 20%.
Results
Among the 913 women, 26 (2.8%) developed PE, including
11 (1.2%) with preterm PE. Prediction for subsequent onset
of PE was performed by the FMF Bayesian theorem-based
model in the 913 cases; 263 cases (28.8%) were classified
as high risk for preterm PE, and 615 cases (67.4%) were
classified as high risk for term PE. Maternal and perinatal
characteristics were compared between the high- and low-
risk groups for preterm PE (number of cases: 263 vs. 650;
Supplementary Table 1) and term PE (number of cases: 615
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vs. 298; Supplementary Table 2). The incidence of preterm
PE in the high-risk group for preterm PE was significantly
higher than that in the low-risk group (3.8% vs. 0.2%, p <
0.05). The incidence of term PE in the high-risk group for
term PE was higher than that in the low-risk group, but this
difference was nonsignificant (2.1% vs. 0.7%, p= 0.10).
The AUROC curves and detection rates of preterm and term
PE at false-positive rates of 5%, 10%, and 20% by com-
bining several parameters based on the model are shown in
Τable 1. The AUROC curve for preterm PE calculated by a
combination of maternal characteristics, MAP, and PlGF
was the highest among the models, though it did not reach
statistical significance. Additionally, the AUROC curve for
term PE calculated by a combination of maternal char-
acteristics and MAP was the highest performing model. The
AUROC curve of the model including maternal character-
istics and MAP was significantly higher than the model
including maternal characteristics, MAP, and UtA-PI (0.751
vs 0.710, p < 0.05), although the AUROC curve of the
model including maternal characteristics and MAP did not
reach statistical significance compared to the other model
except for maternal characteristics, MAP, and UtA-PI.
Table 1 Predictive performance
of screening for preterm and
term PE
Parameters FPR5% FPR10% FPR20% AUROC (95% CI) p value
a b
Preterm PE
* + MAP + UtA-PI + PlGF 73% 91% 91% 0.948 (0.863–0.981) 0.39
* + MAP + UtA-PI 64% 64% 82% 0.909 (0.794–0.962) 0.10 0.07
* + MAP + PlGF 73% 91% 100% 0.962 (0.927–0.981) 0.39
* + MAP 64% 82% 82% 0.909 (0.771–0.968) 0.45 0.21
Term PE
* + MAP + UtA-PI + PlGF 21% 47% 47% 0.729 (0.568–0.850) 0.62
* + MAP + UtA-PI 33% 40% 53% 0.710 (0.541–0.835) 0.56 <0.05
* + MAP + PlGF 27% 47% 53% 0.746 (0.587–0.859) 0.22 0.89
* + MAP 47% 60% 60% 0.751 (0.575–0.870) 0.62
AUROC area under receiver operating characteristic curve, CI confidence interval, MAP mean arterial
pressure, FPR false-positive rate, PIGF maternal serum placental growth factor, PE preeclampsia, UtA-PI
uterine artery pulsatility index
*; Maternal characteristics
a;“p value” refers to compare the AUROC of all parameters (* +MAP + UtA-PI + PlGF) with combination
of other parameters
b;“p value” refers to compare the AUROC of each best model with combination of other parameters. In
screening for preterm PE, the best model is using three parameters (* +MAP + PlGF). In screening for term
PE, the best model is using two parameters(* + MAP)
Fig. 2 Receiver operating
characteristic curves for the
combination of MC, MAP, and
PIGF (―) and the
combination of maternal
characteristics, MAP, PIGF, and
UtA-PI (…) in the prediction of
preterm PE (left). Receiver
operating characteristic curves
for the combination of MC and
MAP (―) and combination of
maternal characteristics, MAP,
PIGF, and UtA-PI (…) in the
prediction of term PE (right).
MAP mean arterial pressure,
MC maternal characteristics, PE
preeclampsia, PIGF maternal
serum placental growth factor,
UtA-PI uterine artery
pulsatility index
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The risk calculation for preterm PE using the best model
had detection rates of 73% (95% confidence interval (CI),
43.4–90.3), 90% (95% CI, 62.3–98.4), and 100% (95% CI,
74.1–100) for fixed false-positive rates of 5%, 10%, and
20%, respectively. The risk calculation for term PE using
the best model had detection rates of 47% (95% CI,
24.8–69.9), 60% (95% CI, 35.8–80.2), and 60% (95% CI,
35.8–80.2) for fixed false-positive rates of 5%, 10%, and
20%, respectively. The results of ROC analysis for pre-
dicting preterm and term PE by the respective best models
are shown in Fig. 2. Furthermore, we constructed calibra-
tion curves to validate our prediction models for preterm
and term PE. These calibration curves showed intercepts of
0.009 (95% CI, −0.071 to 0.089) and 0.013 (95% CI,
−0.004 to 0.030) and calibration slopes of 0.984 (95% CI,
0.723–1.235) and 1.175 (95% CI, 1.016–1.334) for preterm




Variable Preterm PE (n= 11)a Term PE (n= 15)a Unaffected (n= 887)a p value
Maternal age (years) 40 (34–47) 35 (27–40) 34 (22–45) <0.05
Maternal weight (kg) 56 (47–86) 52 (40–75) 52 (37–95) 0.11
Maternal height (cm) 158 (154–168) 157 (147–170) 159 (140–180) 0.68
BMI (kg/m2) 21.7 (19.8–30.5) 20.5 (17.3–30.8) 20.4 (13.7–36.2) <0.05
Primipara 73% (8) 73% (11) 53% (469) 0.12
In vitro fertilization 55% (6) 40% (6) 23% (201) <0.05
Smoking 18% (2) 0% (0) 6% (49) 0.37
CH 36% (4) 13% (2) 0.2% (2) <0.05
DM 9% (1) 0% (0) 0.3% (3) 0.10
Family history of PE 0% (0) 7% (1) 4% (34) 0.57
Parous with 0% (0) 0% (0) 0.6% (6) 0.84
previous PE
GA at screening (days) 92 (85–96) 91 (84–96) 91 (74–103) 0.854
UtA-PI 2.0 (0.9–3.2) 1.3 (0.6–2.6) 1.8 (0.5–3.5) 0.06
UtA-PI MoM 1.26 (0.63–2.06) 0.84 (0.32–1.58) 1.09 (0.34–2.44) 0.13
MAP (mmHg) 91 (78–125) 97 (71–115) 80 (55–110) <0.05
MAP MoM 1.09 (0.96–1.28) 1.08 (0.87–1.28) 0.97 (0.70–1.31) <0.05
PlGF (pg/mL) 19.1(1.1–63.6) 38.7 (15.5–134.8) 36.5 (5.1–124.2) <0.05
PlGF MoM 0.43 (0.02–0.98) 0.82 (0.31–2.19) 0.72 (0.09–2.38) <0.05
BMI body mass index, CH chronic hypertension, DM diabetes mellitus, GA gestational age, MAP mean
arterial pressure, PE preeclampsia, PIGF maternal serum placental growth factor, UtA-PI uterine artery
pulsatility index
aThe results are expressed as either median (range) or % (n)
Fig. 3 Box plots of the multiples of the median value of UtA-PI (left),
MAP (middle), and PlGF (right) between the outcome groups. The
closed box indicates preterm PE group; the hatched box indicates term
PE group; the clear box indicates no PE group. MAP mean arterial
pressure, PE preeclampsia, PIGF maternal serum placental growth
factor, UtA-PI uterine artery pulsatility index
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and term PE, respectively, which suggested that good
agreement did not exist between the predicted risks and
observed incidence in preterm and term PE (Supplementary
Fig. 1).
Maternal characteristics and biomarkers were compared
between preterm PE, term PE, and unaffected cases
(Table 2). The mean MAP MoM was significantly higher,
and the mean PlGF MoM was significantly lower in women
with preterm PE than in those with unaffected pregnancies.
There were no significant differences in the mean UtA-PI
MoM between preterm PE, term PE, and unaffected preg-
nancies (Fig. 3).
Discussion
This study has demonstrated that the FMF Bayes theorem-
based model at 11–13 weeks of gestation could be used to
predict preterm PE in the Japanese population with a
detection rate for preterm PE as high as 91% at a 10% false-
positive rate. Previous publications have reported an overall
detection rate of 75% at a 10% false-positive rate with this
model [4, 5, 13]. The detection rates vary with racial origin,
at 50.0% (95% CI, 6.8–93,2), 68.8% (95% CI, 62.7–75.5),
and 72.8% (95% CI, 62.7–79.1) at a 10% false-positive rate
for East Asian, White, and Afro-Caribbean women,
respectively [4]. Since the detection rate of the FMF model
for the Japanese population is higher than that for the White
and Afro-Caribbean populations, this model can be applied
to screen PE in Japanese women. There are two possible
reasons for the high detection rate of the FMF model in our
study population. First, the risk of PE development in this
population is higher than that in white women (2.8% vs.
2.2% [9, 14]). Moreover, this population exhibited a higher
incidence of preterm PE (1.2%) than East Asian women
(0.67%) [6]. The high incidence of PE might be explained
in part by the fact that our subjects had characteristics such
as advancing maternal age, medical history of CH, and
conception by in vitro fertilization, which are associated
with an increased risk of PE [7]. In particular, 36% (n= 4)
of women who developed preterm PE had CH, compared
with only 0.2% (n= 2) of women without PE. It reflects the
importance of this categorical variable as a risk factor for
PE. Furthermore, our hospital is a tertiary referral hospital
for high-risk pregnancies in the region. Second, strict
compliance with the standardized protocols for the mea-
surements of the parameters may have contributed to the
good screening performance.
Although current studies have demonstrated that the best
model for PE screening is a combination of maternal
characteristics, MAP, UtA-PI, and PlGF, our study
demonstrated that the combination of maternal character-
istics, MAP, and PlGF is sufficient for the prediction of
preterm PE in Japanese women. The measurement of UtA-
PI was not significantly different between the women with
preterm PE, term PE, and unaffected pregnancies (2.0 vs.
1.3 vs. 1.8, p= 0.06), although there was a tendency for the
median value to be higher in the preterm PE group. In
contrast, the measurements of MAP and PlGF were sig-
nificantly different between the outcome groups. Since the
UtA-PI measurements were performed in strict compliance
with the abovementioned protocol with good quality
assessment, the observations with UtA-PI might reflect the
characteristics of this population rather than the instability
of the measurement. In this respect, UtA-PI has a limited
effect on predicting preterm PE compared to other para-
meters in this population.
Previous studies have demonstrated that the performance
of screening for term PE is considerably lower than that of
screening for preterm PE. In this study, the performance in
predicting term PE is consistent with that of previous stu-
dies. In the prediction of term PE, higher performance was
observed with the combination of maternal characteristics
and MAP than with the combination of all parameters. The
mean MAP MoM was higher in the term PE group than in
the preterm PE and unaffected groups (Fig. 3). This might
be caused by differences in the underlying pathophysiolo-
gical mechanisms for preterm and term PE [15]. Although
the cause of PE is not well known, it is initiated by reduced
placental perfusion with failed vascular remodeling,
resulting in the release of factors that lead to maternal
systemic pathophysiological changes [16]. Reduced pla-
cental perfusion and abnormal implantation affect placental
arteries or placenta size, which results in changes in the
UtA-PI or PlGF, leading to the onset of preterm PE. In
contrast, maternal pathophysiology of endothelial dysfunc-
tion is associated with blood pressure, obesity, and other
factors at the time of pregnancy. Maternal endothelial
dysfunction is associated with the subsequent onset of term
PE. Maternal characteristics and MAP have been shown to
be powerful predictors, especially in the prediction of term
PE in this population. The mean UtA-PI MoM was lower,
and PlGF MoM was higher in women with term PE than in
those with unaffected pregnancies. This finding suggested
that term PE had little to do with underlying impaired
placentation in this population. Thus, it has been demon-
strated that the FMF Bayes’ theorem-based model can be
applied for predicting both preterm and term PE in the
Japanese population at 11–13 weeks of gestation.
A limitation of the study relates to the generalizability of
the results, since this study was conducted at a single center,
and the number of cases was relatively small. Our results
cannot confirm that the FMF model is applicable to other
Japanese populations. In addition, compared with previous
studies in which the FMF model has been validated in
different populations [17, 18], our prediction models were
M. Goto et al.
not well calibrated. The lower accuracy of the prediction
probability may be attributed to the small sample size of the
observed incidence. The next step for the clinical applica-
tion of this model will require prospective verification in
more cases at multiple facilities. There might be some
challenges in ensuring prediction accuracy in a nationwide
screening program for PE in Japan. This requires training
for all components of the PE screening program, which is
regularly audited by the FMF. Once the program is estab-
lished, screening for PE can be performed alongside
screening for fetal morphological abnormalities.
In conclusion, we have demonstrated that the FMF Bayes
theorem-based model is effective in predicting preterm PE
in the Japanese population and that it can be implemented as
part of routine prenatal care in Japan.
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